Literature DB >> 6309038

Naloxone.

K A Handal, J L Schauben, F R Salamone.   

Abstract

Naloxone hydrochloride, a synthetic N-allyl derivative of oxymorphone, is an effective agent for the reversal of the cardiovascular and respiratory depression associated with narcotic and possibly some non-narcotic overdoses. It is essentially a pure narcotic antagonist, is relatively safe, and is a useful diagnostic and therapeutic agent. Due to naloxone's pharmacokinetic profile, a continuous infusion protocol is recommended when prolonged narcotic antagonist effects are required. The complex pharmacodynamics of naloxone, specifically relating to endorphin receptor sites, focus its potential use in a variety of clinical situations as continuing research illustrates the association of endogenous opioid compounds with various disease states.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6309038     DOI: 10.1016/s0196-0644(83)80343-6

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  29 in total

Review 1.  The pharmacological treatment of opioid addiction--a clinical perspective.

Authors:  Philipp Lobmaier; Michael Gossop; Helge Waal; Jorgen Bramness
Journal:  Eur J Clin Pharmacol       Date:  2010-02-19       Impact factor: 2.953

2.  Sex and opioid maintenance dose influence response to naloxone in opioid-dependent humans: a retrospective analysis.

Authors:  Mohit P Chopra; Zachary Feldman; Michael J Mancino; Alison Oliveto
Journal:  Pharmacol Biochem Behav       Date:  2008-10       Impact factor: 3.533

3.  Poisoning and severe ventilatory depression after oral ingestion of the industrially produced analgesic mixture tilidine with naloxone (Valoron N solution)

Authors:  M Krüger; R Regenthal; M Richter; R Preiss
Journal:  Intensive Care Med       Date:  1998-07       Impact factor: 17.440

4.  Influence of naloxone on the effects of high frequency transcutaneous electrical nerve stimulation in angina pectoris induced by atrial pacing.

Authors:  C Mannheimer; H Emanuelsson; F Waagstein; C Wilhelmsson
Journal:  Br Heart J       Date:  1989-07

5.  Nanoconjugated NAP as a Potent and Periphery Selective Mu Opioid Receptor Modulator To Treat Opioid-Induced Constipation.

Authors:  Guoyan G Xu; Olga Yu Zolotarskaya; Dwight A Williams; Yunyun Yuan; Dana E Selley; William L Dewey; Hamid I Akbarali; Hu Yang; Yan Zhang
Journal:  ACS Med Chem Lett       Date:  2016-11-21       Impact factor: 4.345

6.  Monoclonal Antibodies for Combating Synthetic Opioid Intoxication.

Authors:  Lauren C Smith; Paul T Bremer; Candy S Hwang; Bin Zhou; Beverly Ellis; Mark S Hixon; Kim D Janda
Journal:  J Am Chem Soc       Date:  2019-06-25       Impact factor: 15.419

7.  Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl.

Authors:  Teijo I Saari; Kari Laine; Mikko Neuvonen; Pertti J Neuvonen; Klaus T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  2007-11-07       Impact factor: 2.953

8.  Case files of the University of Massachusetts fellowship in medical toxicology: lethal dose of opioids contained in an elastomeric capsule labeled as vancomycin.

Authors:  James Courtney; Edward Boyer
Journal:  J Med Toxicol       Date:  2008-09

9.  Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation.

Authors:  Peter Deibert; Carola Xander; Hubert E Blum; Gerhild Becker
Journal:  Core Evid       Date:  2010-06-15

10.  Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain.

Authors:  A Sandner-Kiesling; P Leyendecker; M Hopp; L Tarau; J Lejcko; W Meissner; P Sevcik; M Hakl; R Hrib; R Uhl; H Dürr; K Reimer
Journal:  Int J Clin Pract       Date:  2010-03-29       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.